Alexion Pharmaceuticals (ALXN) : During the past 4 weeks, traders have been relatively bearish on Alexion Pharmaceuticals (ALXN), hence the stock is down -3.9% when compared to the S&P 500 during the same period. However, in the past 1 week, the selling of the stock is down by -0.55% relative to the S&P 500. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 0.93% in the last 1 week, and is up 0.3% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock. The stock has recorded a 20-day Moving Average of 3.75% and the 50-Day Moving Average is 6.46%.
Alexion Pharmaceuticals (NASDAQ:ALXN): During Fridays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $126.37 and $124.96 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $126.87. The buying momentum continued till the end and the stock did not give up its gains. It closed at $125.58, notching a gain of 0.34% for the day. The total traded volume was 1,606,479 . The stock had closed at $125.15 on the previous day.
The company Insiders own 4.41% of Alexion Pharmaceuticals shares according to the proxy statements. In the past twelve weeks, the net percent change held by company insiders has changed by -3.86% . Institutional Investors own 98.92% of Alexion Pharmaceuticals shares. During last six month period, the net percent change held by insiders has seen a change of -2.23%. In a related news, The Securities and Exchange Commission has divulged that Moriarty John B, officer (EVP & General Counsel) of Alexion Pharmaceuticals Inc, had unloaded 918 shares at an average price of $135.72 in a transaction dated on June 13, 2016. The total value of the transaction was worth $124,591.
Alexion Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of life-transforming therapeutic products. As of June 23, 2015, the Company had eight product candidates in clinical trials for 11 indications. The Companys product pipeline includes complement inhibitor portfolio, metabolic rare disease portfolio and preclinical candidates. Its complement inhibitor portfolio includes Soliris, ALXN1007, ALXN1210 and ALXN5500. Its metabolic rare disease portfolio includes Strensiq, Kanuma, ALXN1101 and SBC-103. The Companys preclinical candidates include mRNA Therapies, SBC-105 and other complement inhibitors. Its Soliris is approved for the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS), two life-threatening ultra-rare disorders.